Cultural Heritage in Europe: A commitment for socioeconomic change from managing our past II

Diseño web, apoyo RRSS: Empresa Jansá Cultura y Tecnología https://appcultura.comEl proyecto formará en el Patrimonio Cultural existente en la Unión Europea desde su gestión. Supone actividades como: 1. Conocer los bienes culturales desde la visión crítica de los procesos de patrimonialización hasta la catalogación e inventario. 2 Planificar su financiación, legislación o la ordenación urbanística y territorial. 3. Controlar las acciones ilícitas que pueden deteriorarlos, así como la venta o la transmisión de estos bienes. 4. Plantear su socialización desde la interpretación y la difusión en ámbitos formales e informales, desde estrategias de turismo, tecnológicas o de redes sociales, así como realizar procesos participativos, de implicación de la sociedad civil y organizaciones interesadas en la toma de decisiones sobre su tratamiento. 5. Ser capaces de evaluar a corto, largo y medio plazo y desde múltiples perspectivas, incluida la del impacto socioeconómico. De la importancia del tema habla por si sola la declaración del Parlamento Europeo para la celebración del Año 2018 y que reproducimos (http://www.consilium.europa.eu/es/press/press-releases/2017/02/09-cultural-heritage/): " Año Europeo del Patrimonio Cultural en 2018: celebración de la diversidad y la riqueza de nuestro patrimonio europeo, cuyos objetivos son: - Promover la diversidad cultural, el diálogo intercultural y la cohesión social; - Poner de relieve la contribución económica del patrimonio cultural a los sectores cultural y de la creación, en particular a las pequeñas y medianas empresas, y al desarrollo local y regional; - Hacer hincapié en el papel del patrimonio cultural en las relaciones exteriores de la UE, por ejemplo, en la prevención de conflictos, la reconciliación tras estos y la reconstrucción del patrimonio cultural destruido " Abordar estos temas requiere una formación transdisciplinar, que aporta el equipo de docentes de la Universidad Complutense de Madrid y de la Universidad Politécnica de Madrid pertenecientes a las siguientes áreas de conocimiento: historia, historia del arte, geografía, arqueología, economía, sociología, psicología, derecho, arquitectura, ingeniería de las telecomunicaciones y de caminos, canales y puertos. A ellos se le suma una trayectoria de cerca de 30 años en los temas referidos, siendo nuestros centros pioneros en España para impartir esa formación y sin lugar a dudas innovadores en la transversalidad con la que las hemos impulsado en nuestras distintas facultades y escuelas, donde no existe el área de conocimiento como tal. Participamos miembros de varios grupos de investigación, como el de Gestión del Patrimonio Cultural, Patrimonio Turismo y Desarrollo o Paisajes Culturales. Destacan responsabilidades y docencias en Másteres como el de Conservación y Restauración en Patrimonio Arquitectónico, de la UPM o el de Museos y Patrimonio Histórico Artístico de la UCM, lineas de doctorado en Turismo y Desarrollo, asignaturas de grado y posgrados como Patrimonio Urbano, Paisaje Cultural y Ordenación Territorial o la gestión del patrimonio arqueológico. Así mismo la mayoría de nosotros hemos sido evaluados positivamente por el programa Docentia, y hemos participado y dirigido otros proyectos de innovación como el que se encuentra en los antecedentes a este sobre Patrimonio Cultural en CIU y el del decanato de la Fac. Geografía e Historia de Living Unilab sobre APs y ecosistemas de aprendizaje. Iniciativas con las que continuaremos participando. Pero, sin lugar a dudas, ha sido el Máster Interuniversitario Patrimonio Cultural en el S.XXI: Gestión e investigación, un motor de arranque para iniciativas conjuntas entre este equipo, a través del Campus de Excelencia Internacional, y es justo este año cuando se pone en marcha y podremos allí explorar gran parte de nuestras innovaciones recogidas en este proyecto. A estos esfuerzos se suma el alumnado: 13 estudiantes de grados y posgrados comprometidxs con la oportunidad que nos ofrece el pasado. No hay mejor aval para nuestra propuesta.The Educational Innovation Project “Cultural Heritage in Europe: a commitment for socioeconomic change from managing our past” of the Complutense University of Madrid together with the Technical University of Madrid, took advantage of the celebration of the European Year of Cultural Heritage 2018 to open new paths of transversal and multidisciplinary knowledge in the field of Cultural Heritage by applying a type of classroom teaching that would allow students to offer projects that could have an impact on society and contribute to meeting the objectives set by the European Commission for this year's celebration. From a European perspective, the project has completed a triple aspect: researcher, education and public service when working and disseminating Cultural Heritage among the population of Madrid and Europe. The work has been done on disciplines as diverse as Architecture, History, Civil Engineering, Geography, Tourism, etc. to compose from the different subjects involved a speech that will contribute to this field.Depto. de Prehistoria, Historia Antigua y ArqueologíaFac. de Geografía e HistoriaFALSEAyuntamiento de Madrid/Foro de Empresas por Madridsubmitte

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality

Vivir la Ética

Resumen tomado de la portada. Existe una versión de 2005, cuya signatura es S/1022Dentro del programa -Internet en el aula-, el recurso Vivir la Ética constituye una invitación a crecer en Ética y en valores de un modo práctico y activo, gracias a la experiencia y al compromiso personal. Por, eso desarrolla un método formativo cuyo principio fundamental es la personalización. Su método pedagógico consiste esencialmente en adecuar los materiales y actividades a su interlocutor fundamental: los jóvenes.MadridBiblioteca de Educación del Ministerio de Educación, Cultura y Deporte; Calle San Agustín 5 -3 Planta; 28014 Madrid; Tel. +34917748000; [email protected]

Cristales y minerales

[ES] Trata sobre la formación de los minerales y la cristalografía.[EN] This work is about the minerals and the crystallography

Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

(1) Background: Despite the prognostic improvements achieved with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), a minority of patients still fail TKIs. The recent introduction of asciminib may be a promising option in intolerant patients, as it is a first-in-class inhibitor with a more selective mechanism of action different from the ATP-competitive inhibition that occurs with TKIs. Therefore, our goal was to analyze toxicities shown with asciminib as well as to study cross-toxicity with previous TKIs. (2) Methods: An observational, multicenter, retrospective study was performed with data from 77 patients with CML with therapeutic failure to second-generation TKIs who received asciminib through a managed-access program (MAP) (3) Results: With a median follow-up of 13.7 months, 22 patients (28.5%) discontinued treatment: 32% (7/22) due to intolerance and 45% (10/22) due to resistance. Fifty-five percent of the patients reported adverse effects (AEs) with asciminib and eighteen percent grade 3&ndash;4. Most frequent AEs were: fatigue (18%), thrombocytopenia (17%), anemia (12%), and arthralgias (12%). None of the patients experienced cardiovascular events or occlusive arterial disease. Further, 26%, 25%, and 9% of patients required dose adjustment, temporary suspension, or definitive discontinuation of treatment, respectively. Toxicities under asciminib seemed lower than with prior TKIs for anemia, cardiovascular events, pleural/pericardial effusion, diarrhea, and edema. Cross-toxicity risk was statistically significant for thrombocytopenia, anemia, neutropenia, fatigue, vomiting, and pancreatitis. (4) Conclusion: Asciminib is a molecule with a good safety profile and with a low rate of AEs. However, despite its new mechanism of action, asciminib presents a risk of cross-toxicity with classical TKIs for some AEs

Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

Simple Summary After the recent irruption of asciminib into the therapeutic arsenal for chronic myeloid leukemia, real-life data remain scarce to determine which patients may benefit most from this drug. Data on the efficacy of the drug in real-world setting have been reported, but a detailed analysis of the toxicity profile and the influence of prior intolerance to classical tyrosine kinase inhibitors (TKIs) has not been performed. The aim of the present analysis is to study in detail the toxicity profile of asciminib as well as to describe the risk of cross-toxicity with classical TKIs. These results may help to select the patient profile with the best chance of therapeutic success with asciminib monotherapy. (1) Background: Despite the prognostic improvements achieved with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), a minority of patients still fail TKIs. The recent introduction of asciminib may be a promising option in intolerant patients, as it is a first-in-class inhibitor with a more selective mechanism of action different from the ATP-competitive inhibition that occurs with TKIs. Therefore, our goal was to analyze toxicities shown with asciminib as well as to study cross-toxicity with previous TKIs. (2) Methods: An observational, multicenter, retrospective study was performed with data from 77 patients with CML with therapeutic failure to second-generation TKIs who received asciminib through a managed-access program (MAP) (3) Results: With a median follow-up of 13.7 months, 22 patients (28.5%) discontinued treatment: 32% (7/22) due to intolerance and 45% (10/22) due to resistance. Fifty-five percent of the patients reported adverse effects (AEs) with asciminib and eighteen percent grade 3-4. Most frequent AEs were: fatigue (18%), thrombocytopenia (17%), anemia (12%), and arthralgias (12%). None of the patients experienced cardiovascular events or occlusive arterial disease. Further, 26%, 25%, and 9% of patients required dose adjustment, temporary suspension, or definitive discontinuation of treatment, respectively. Toxicities under asciminib seemed lower than with prior TKIs for anemia, cardiovascular events, pleural/pericardial effusion, diarrhea, and edema. Cross-toxicity risk was statistically significant for thrombocytopenia, anemia, neutropenia, fatigue, vomiting, and pancreatitis. (4) Conclusion: Asciminib is a molecule with a good safety profile and with a low rate of AEs. However, despite its new mechanism of action, asciminib presents a risk of cross-toxicity with classical TKIs for some AEs